Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Start-ups
Gene therapy start-up Freeline Therapeutics raises $116 million
by Ryan Cross
June 24, 2018
| A version of this story appeared in
Volume 96, Issue 26
The U.K-. and Germany-based gene therapy start-up Freeline Therapeutics has raised $116 million in series B financing, most of it coming from British life sciences investment company Syncona. Freeline will use the money to develop adeno-associated virus (AAV) gene therapies for hemophilia B, caused by a deficiency in clotting factor IX, and for Fabry disease, caused by a deficiency of a lipid-metabolizing enzyme. Gene therapy clinical trials for those diseases are already under way at competitors Spark Therapeutics and Avrobio.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X